Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice

Yan, Shang Xue; Deng, Xiao; Wang, Qingtong; Sun, Xiao; Wei, Wei

doi:10.1038/aps.2015.76

Cited by 38 publications

(26 citation statements)

References 47 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mtx was capable of controlling the inflammatory process as observed in Figure 1 ; it also provoked an increment of protein elimination in urine; this represents one of the collateral effects previously reported for the strain of mice used in this model [ 26 ] and this is what determines the deleterious capacity of Mtx on the nephron. The anti-inflammatory effect of Pdn also protected the nephrons from damage since proteinuria was not provoked, as has previously been reported in laboratory tests and clinical studies [ 27 , 28 ], where it has been suggested that Pdn has the capacity to improve the nephron function.…”

Section: Discussionsupporting

confidence: 67%

“…Pdn managed to reduce articular inflammation of the joints caused by TMPD, however, was not able to control the increase in antinuclear autoantibodies titers. Some reports indicate that daily intragastric administration of Pdn at a dose of 2.5 mg/kg for three weeks blocked the increase of antinuclear autoantibodies titers associated with SLE development in MRL/lpr mice [ 28 ]; the Pdn treatment used in this assay did not have the capacity to modify the antinuclear autoimmune response, it can be considered that increasing the dose of this drug up to 5 mg/kg in this same treatment, it could generate a decrease in the antinuclear autoantibodies titers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunomodulatory Effect of Agave tequilana Evaluated on an Autoimmunity Like-SLE Model Induced in Balb/c Mice with Pristane

et al. 2017

View full text Add to dashboard Cite

In this work, the immunomodulatory activity of the acetone extract and the fructans obtained from Agave tequilana were evaluated, on the systemic autoimmunity type-SLE model generated by the administration of 2,6,10,14-tetramethylpentadecane (TMPD, also known as pristane) on Balb/c female mice. The systemic autoimmunity type-SLE was observed seven months after the application of TMPD, in which the animals from the negative control group (animals with damage and without any other treatment) developed articular inflammation, proteinuria, an increment of the antinuclear antibody titters and tissue pro-inflammatory cytokines levels (IL-1β, IL-6, TNF-α e IFN-γ) as well as the anti-inflammatory cytokine IL-10. The administration of the different treatments and the extracts of A. tequilana, provoked the decrease of: articular inflammation, the development of proteinuria, ssDNA/dsDNA antinuclear antibody titters and cytokines IL-1β, IL-6, TNF-α, IFN-γ and IL-10. The phytochemical analysis of the acetone extract identified the presence of the following compounds: β-sitosterol glycoside; 3,7,11,15-tetramethyl-2-hexadecen-1-ol (phytol); octadecadienoic acid-2,3-dihydroxypropyl ester; stigmasta-3,5-dien-7-one; cycloartenone and cycloartenol. Therefore, A. tequilana contains active compounds with the capacity to modify the evolution of the systemic autoimmunity type-SLE on a murine model.

show abstract

Section: Discussionsupporting

confidence: 67%

Section: Discussionmentioning

confidence: 99%

Immunomodulatory Effect of Agave tequilana Evaluated on an Autoimmunity Like-SLE Model Induced in Balb/c Mice with Pristane

et al. 2017

View full text Add to dashboard Cite

show abstract

“…B cell subtypes, and the mechanisms of antibody production and maintenance, are highly diverse, and likewise the susceptibility of autoantibody-secreting plasma cells to therapies seems to be dependent on their tissue localization ( 1 ). Generally, conventional immunosuppressive therapy, using either steroids or cytostatic drugs, is commonly used in many autoimmune diseases and partly inhibits autoantibody production ( 2 – 5 ). At present, several drugs that specifically target B cells or plasma cells are either in clinical use or under development and promise to be very efficient for the treatment of various autoimmune diseases ( 6 – 8 ).…”

Section: Introductionmentioning

confidence: 99%

Targeting B Cells and Plasma Cells in Autoimmune Diseases

2018

View full text Add to dashboard Cite

Success with B cell depletion using rituximab has proven the concept that B lineage cells represent a valid target for the treatment of autoimmune diseases, and has promoted the development of other B cell targeting agents. Present data confirm that B cell depletion is beneficial in various autoimmune disorders and also show that it can worsen the disease course in some patients. These findings suggest that B lineage cells not only produce pathogenic autoantibodies, but also significantly contribute to the regulation of inflammation. In this review, we will discuss the multiple pro- and anti-inflammatory roles of B lineage cells play in autoimmune diseases, in the context of recent findings using B lineage targeting therapies.

show abstract

“…Firstly, GC induce apoptosis in B cells at all developmental stages (78–80). In addition, GC suppress plasma cell differentiation potentially via down-regulation of Blimp1 and Bcl6 (81, 82). Finally, GC may also directly affect the production of IgG antibodies through inhibition of activation-induced cytidine deaminase (AICDA), an enzyme required for class switch recombination and somatic hypermutation (83).…”

Section: The Mechanism Of Gc Action In the Treatment Of Slementioning

confidence: 99%

Could GILZ Be the Answer to Glucocorticoid Toxicity in Lupus?

2019

View full text Add to dashboard Cite

Glucocorticoids (GC) are used globally to treat autoimmune and inflammatory disorders. Their anti-inflammatory actions are mainly mediated via binding to the glucocorticoid receptor (GR), creating a GC/GR complex, which acts in both the cytoplasm and nucleus to regulate the transcription of a host of target genes. As a result, signaling pathways such as NF-κB and AP-1 are inhibited, and cell activation, differentiation and survival and cytokine and chemokine production are suppressed. However, the gene regulation by GC can also cause severe side effects in patients. Systemic lupus erythematosus (SLE or lupus) is a multisystem autoimmune disease, characterized by a poorly regulated immune response leading to chronic inflammation and dysfunction of multiple organs, for which GC is the major current therapy. Long-term GC use, however, can cause debilitating adverse consequences for patients including diabetes, cardiovascular disease and osteoporosis and contributes to irreversible organ damage. To date, there is no alternative treatment which can replicate the rapid effects of GC across multiple immune cell functions, effecting disease control during disease flares. Research efforts have focused on finding alternatives to GC, which display similar immunoregulatory actions, without the devastating adverse metabolic effects. One potential candidate is the glucocorticoid-induced leucine zipper (GILZ). GILZ is induced by low concentrations of GC and is shown to mimic the action of GC in several inflammatory processes, reducing immunity and inflammation in in vitro and in vivo studies. Additionally, GILZ has, similar to the GC-GR complex, the ability to bind to both NF-κB and AP-1 as well as DNA directly, to regulate immune cell function, while potentially lacking the GC-related side effects. Importantly, in SLE patients GILZ is under-expressed and correlates negatively with disease activity, suggesting an important regulatory role of GILZ in SLE. Here we provide an overview of the actions and use of GC in lupus, and discuss whether the regulatory mechanisms of GILZ could lead to the development of a novel therapeutic for lupus. Increased understanding of the mechanisms of action of GILZ, and its ability to regulate immune events leading to lupus disease activity has important clinical implications for the development of safer anti-inflammatory therapies.

show abstract

Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice

Abstract: Prednisone treatment restricts B lymphocyte differentiation into plasma cells in MRL/lpr mice, which may be correlated with the inhibition of IL-21 production and the restoration of the balance between Blimp-1 and Bcl-6.

Cited by 38 publications

References 47 publications

Immunomodulatory Effect of Agave tequilana Evaluated on an Autoimmunity Like-SLE Model Induced in Balb/c Mice with Pristane

Immunomodulatory Effect of Agave tequilana Evaluated on an Autoimmunity Like-SLE Model Induced in Balb/c Mice with Pristane

Targeting B Cells and Plasma Cells in Autoimmune Diseases

Could GILZ Be the Answer to Glucocorticoid Toxicity in Lupus?

Contact Info

Product

Resources

About